The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...

Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NYSE: NVO), famously the company behind Wegovy, and ...

The spot makes lofty claims about weight-loss drugs offered by the telehealth company Hims & Hers, but says little about ...

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has ...